Skip to content
Business Segments · Total other segment expense, net

North American Pharmaceutical — Total other segment expense, net

McKesson North American Pharmaceutical — Total other segment expense, net remained flat by 0.0% to $83.25B in Q4 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.6%, from $87.27B to $83.25B. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ4 2026May 8, 2026

How to read this metric

A decrease relative to revenue indicates improved operational efficiency and better cost control within the segment.

Detailed definition

This metric captures the net total of various operational expenses not directly attributable to the cost of goods sold o...

Peer comparison

Standard segment-level expense reporting found in the financial disclosures of large-scale distribution companies.

Metric ID: mck_segment_north_american_pharmaceutical_total_other_segment_expense_net

Historical Data

8 periods
 Q3 '24Q4 '24Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Value$79.67B$80.45B$85.63B$87.27B$83.25B$83.25B$83.25B$83.25B
QoQ Change+1.0%+6.4%+1.9%-4.6%+0.0%+0.0%+0.0%
YoY Change+7.5%+8.5%-2.8%-4.6%
Range$79.67B$87.27B
CAGR+2.5%
Avg YoY Growth+2.1%
Median YoY Growth+2.3%
Current Streak3 quarters growth

Frequently Asked Questions

What is McKesson's north american pharmaceutical — total other segment expense, net?
McKesson (MCK) reported north american pharmaceutical — total other segment expense, net of $83.25B in Q4 2026.
How has McKesson's north american pharmaceutical — total other segment expense, net changed year-over-year?
McKesson's north american pharmaceutical — total other segment expense, net decreased by 4.6% year-over-year, from $87.27B to $83.25B.
What does north american pharmaceutical — total other segment expense, net mean?
The net total of miscellaneous operating expenses incurred by the North American Pharmaceutical segment.